SML3117

N-Desethyl sunitinib hydrochloride

≥98% (HPLC)

• 別名: 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)amide hydrochloride, N-Desethylsunitinib hydrochloride, N-[2-(Ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide hydrochloride, SU 12662 hydrochloride, SU12662 hydrochloride
• 実験式（ヒル表記法）: C₂₀H₂₃FN₄O₂ · xHCl
• CAS番号: 356068-97-8
• 分子量: 370.42 (free base basis)
• MDL番号: MFCD18252482
• UNSPSCコード: 12352200
• NACRES: NA.77

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• 形状: powder
• 保管条件: desiccated
• 色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear (warmed)
• 保管温度: 2-8°C
• InChI: 1S/C20H23FN4O2/c1-4-22-7-8-23-20(27)18-11(2)17(24-12(18)3)10-15-14-9-13(21)5-6-16(14)25-19(15)26/h5-6,9-10,22,24H,4,7-8H2,1-3H3,(H,23,27)(H,25,26)/b15-10-
• InChI Key: LIZNIAKSBJKPQC-GDNBJRDFSA-N

詳細

生物化学的／生理学的作用

N-Desethyl sunitinib is a multi-target tyrosine kinase inhibitor that is a major active metabolite of an anticancer drug sunitinib. N-Desethyl sunitinib has a similar kinase inhibitory effect as sunitinib. In patients, plasma sunitinib and N-desethyl sunitinib accounts for 42% and 24%, respectively. Thus N-desethyl sunitinib accounts for one third of the therapeutic effect of oral sunitinib.

安全性情報

• ピクトグラム: GHS08,GHS09
• シグナルワード: Warning
• 危険有害性情報: H361d,H373,H410
• 注意書き: P202 - P260 - P273 - P280 - P308 + P313 - P391
• 危険有害性の分類: Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 2 - STOT RE 2
• ターゲットの組織: blood vessel,Bone marrow
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable